Evolus (EOLS) News Today $7.63 +0.11 (+1.46%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$7.64 +0.01 (+0.13%) As of 08/29/2025 06:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock EOLS Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Evolus, Inc. $EOLS Shares Sold by Tri Locum Partners LPAugust 30 at 8:04 AM | marketbeat.comEvolus, Inc. $EOLS Shares Purchased by Vanguard Group Inc.August 29 at 3:13 AM | marketbeat.comInsider Selling: Evolus (NASDAQ:EOLS) CMO Sells 5,722 Shares of StockAugust 27, 2025 | insidertrades.comStonepine Capital Management LLC Has $13.65 Million Stock Holdings in Evolus, Inc. $EOLSAugust 26, 2025 | marketbeat.comEvolus, Inc. $EOLS Stock Holdings Boosted by Algert Global LLCAugust 26, 2025 | marketbeat.comEvolus announces Evolysse Sculpt trial meets primary endpointAugust 25, 2025 | msn.comEvolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic BootcampAugust 25, 2025 | businesswire.comNuveen LLC Invests $12.33 Million in Evolus, Inc. $EOLSAugust 24, 2025 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) Director Buys $204,600.00 in StockAugust 20, 2025 | marketbeat.comEvolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel ProductAugust 20, 2025 | businesswire.comEvolus, Inc. (NASDAQ:EOLS) Director Acquires $204,600.00 in StockAugust 19, 2025 | insidertrades.comConnor Clark & Lunn Investment Management Ltd. Makes New Investment in Evolus, Inc. $EOLSAugust 19, 2025 | marketbeat.comEvolus Appoints New Principal Financial OfficerAugust 15, 2025 | theglobeandmail.comEvolus (EOLS) Q2 Revenue Rises 4%August 15, 2025 | theglobeandmail.comAltium Capital Management LLC Reduces Holdings in Evolus, Inc. (NASDAQ:EOLS)August 14, 2025 | marketbeat.comThe Consensus EPS Estimates For Evolus, Inc. (NASDAQ:EOLS) Just Fell DramaticallyAugust 10, 2025 | finance.yahoo.comEvolus, Inc. (NASDAQ:EOLS) Receives Average Rating of "Moderate Buy" from AnalystsAugust 10, 2025 | marketbeat.comEvolus (NASDAQ:EOLS) Stock Rating Lowered by Wall Street ZenAugust 10, 2025 | marketbeat.comAnalysts Have Lowered Expectations For Evolus, Inc. (NASDAQ:EOLS) After Its Latest ResultsAugust 8, 2025 | finance.yahoo.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 8, 2025 | businesswire.comEvolus (NASDAQ:EOLS) Price Target Cut to $18.00 by Analysts at BTIG ResearchAugust 7, 2025 | marketbeat.comEvolus, Inc. Advances Safety Study of NUCEIVA for Glabellar LinesAugust 7, 2025 | tipranks.comHC Wainwright Has Lowered Expectations for Evolus (NASDAQ:EOLS) Stock PriceAugust 7, 2025 | marketbeat.comEvolus (NASDAQ:EOLS) Lowered to Hold Rating by Needham & Company LLCAugust 7, 2025 | marketbeat.comEvolus, Inc. Faces Financial Instability Amid Economic Uncertainty and Consumer Spending RisksAugust 7, 2025 | tipranks.comNeedham Downgrades Evolus (EOLS)August 7, 2025 | msn.comEvolus (NASDAQ:EOLS) Hits New 12-Month Low After Analyst DowngradeAugust 7, 2025 | marketbeat.comEvolus plunges after Q2 miss, guidance cut; Needham downgradesAugust 6, 2025 | msn.comEvolus (NASDAQ:EOLS) Announces Earnings Results, Misses Expectations By $0.21 EPSAugust 6, 2025 | marketbeat.comEvolus price target lowered to $20 from $27 at H.C. WainwrightAugust 6, 2025 | msn.comEvolus, Inc. Reports Q2 2025 Financial ResultsAugust 5, 2025 | tipranks.comA Look Ahead: Evolus's Earnings ForecastAugust 5, 2025 | benzinga.comEvolus, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 5, 2025 | seekingalpha.comEvolus Reports Second Quarter 2025 Financial Results and Provides Business UpdatesAugust 5, 2025 | businesswire.com61,682 Shares in Evolus, Inc. (NASDAQ:EOLS) Bought by XTX Topco LtdAugust 5, 2025 | marketbeat.comEvolus (NASDAQ:EOLS) Reaches New 52-Week Low - What's Next?August 2, 2025 | marketbeat.comEvolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau® as a Top Performer Among Leading NeurotoxinsJuly 31, 2025 | businesswire.comY Intercept Hong Kong Ltd Buys New Holdings in Evolus, Inc. (NASDAQ:EOLS)July 29, 2025 | marketbeat.comEvolus (EOLS) Expected to Announce Earnings on WednesdayJuly 23, 2025 | marketbeat.comEvolus to Report Second Quarter Financial Results on August 5, 2025July 22, 2025 | businesswire.comEvolus - A Slightly Risky Buy Ahead Of Q2 EarningsJuly 21, 2025 | seekingalpha.comRice Hall James & Associates LLC Sells 26,887 Shares of Evolus, Inc. (NASDAQ:EOLS)July 14, 2025 | marketbeat.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)July 11, 2025 | businesswire.comEvolus Expands Global Footprint with Introduction of Nuceiva® (botulinum toxin type A) in FranceJuly 9, 2025 | businesswire.comEvolus (NASDAQ:EOLS) Shares Down 5.5% After Insider SellingJune 17, 2025 | marketbeat.comDavid Moatazedi Sells 16,582 Shares of Evolus, Inc. (NASDAQ:EOLS) StockJune 16, 2025 | marketbeat.comInsider Selling: Evolus, Inc. (NASDAQ:EOLS) Insider Sells 111,323 Shares of StockJune 16, 2025 | marketbeat.comEvolus, Inc. (NASDAQ:EOLS) Shares Bought by Assenagon Asset Management S.A.June 15, 2025 | marketbeat.comEvolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 13, 2025 | businesswire.comEvolus, Inc. Common Stock (EOLS) Stock ForecastsJune 11, 2025 | ca.finance.yahoo.com Get Evolus News Delivered to You Automatically Sign up to receive the latest news and ratings for EOLS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. EOLS Media Mentions By Week EOLS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EOLS News Sentiment▼1.181.09▲Average Medical News Sentiment EOLS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EOLS Articles This Week▼105▲EOLS Articles Average Week Get the Latest News and Ratings for EOLS and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Evolus and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Adaptive Biotechnologies News Today Sarepta Therapeutics News Today ANI Pharmaceuticals News Today Arcutis Biotherapeutics News Today Vericel News Today Dyne Therapeutics News Today Apogee Therapeutics News Today Twist Bioscience News Today Beam Therapeutics News Today Cidara Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EOLS) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evolus, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Evolus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free EOLS Stock Alerts